Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 11 studies | 29% ± 12% | |
peripheral blood | 6 studies | 20% ± 5% | |
kidney | 6 studies | 25% ± 5% | |
intestine | 6 studies | 24% ± 12% | |
brain | 6 studies | 21% ± 5% | |
eye | 5 studies | 28% ± 13% | |
pancreas | 3 studies | 40% ± 7% | |
uterus | 3 studies | 31% ± 21% | |
thymus | 3 studies | 35% ± 13% | |
liver | 3 studies | 25% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 2439.45 | 258 / 258 | 100% | 13.62 | 230 / 230 |
brain | 100% | 2162.94 | 2642 / 2642 | 100% | 19.77 | 705 / 705 |
esophagus | 100% | 1570.91 | 1445 / 1445 | 100% | 8.94 | 183 / 183 |
prostate | 100% | 1380.32 | 245 / 245 | 100% | 18.21 | 502 / 502 |
breast | 100% | 1341.50 | 459 / 459 | 100% | 17.25 | 1117 / 1118 |
thymus | 100% | 1140.12 | 652 / 653 | 100% | 16.07 | 605 / 605 |
uterus | 100% | 1221.62 | 170 / 170 | 100% | 13.89 | 458 / 459 |
ovary | 100% | 1157.16 | 180 / 180 | 100% | 10.67 | 429 / 430 |
skin | 100% | 1572.70 | 1805 / 1809 | 100% | 12.07 | 471 / 472 |
bladder | 100% | 1414.10 | 21 / 21 | 99% | 12.50 | 499 / 504 |
kidney | 100% | 1378.33 | 89 / 89 | 99% | 10.96 | 892 / 901 |
liver | 99% | 762.40 | 223 / 226 | 100% | 11.79 | 406 / 406 |
intestine | 100% | 1250.82 | 965 / 966 | 98% | 9.49 | 517 / 527 |
stomach | 100% | 918.97 | 358 / 359 | 98% | 8.93 | 281 / 286 |
lung | 98% | 912.45 | 566 / 578 | 100% | 11.70 | 1154 / 1155 |
pancreas | 96% | 585.72 | 316 / 328 | 99% | 10.22 | 177 / 178 |
adipose | 100% | 1304.96 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1770.83 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 13.22 | 29 / 29 |
spleen | 100% | 954.92 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.11 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.07 | 1 / 1 |
muscle | 100% | 1625.15 | 802 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 12.80 | 79 / 80 |
heart | 95% | 1101.97 | 821 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 47% | 383.50 | 441 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006289 | Biological process | nucleotide-excision repair |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0006362 | Biological process | transcription elongation by RNA polymerase I |
GO_0006367 | Biological process | transcription initiation at RNA polymerase II promoter |
GO_0006294 | Biological process | nucleotide-excision repair, preincision complex assembly |
GO_0000462 | Biological process | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) |
GO_0071480 | Biological process | cellular response to gamma radiation |
GO_0005730 | Cellular component | nucleolus |
GO_0005669 | Cellular component | transcription factor TFIID complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000439 | Cellular component | transcription factor TFIIH core complex |
GO_0005675 | Cellular component | transcription factor TFIIH holo complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005515 | Molecular function | protein binding |
Gene name | GTF2H5 |
Protein name | General transcription factor IIH subunit 5 General transcription factor IIH subunit 5 (General transcription factor IIH polypeptide 5) (TFB5 ortholog) (TFIIH basal transcription factor complex TTD-A subunit) (TFIIH subunit p8) |
Synonyms | TTDA C6orf175 |
Description | FUNCTION: Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, which is involved in general and transcription-coupled nucleotide excision repair (NER) of damaged DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II. In NER, TFIIH acts by opening DNA around the lesion to allow the excision of the damaged oligonucleotide and its replacement by a new DNA fragment. In transcription, TFIIH has an essential role in transcription initiation. When the pre-initiation complex (PIC) has been established, TFIIH is required for promoter opening and promoter escape. Phosphorylation of the C-terminal tail (CTD) of the largest subunit of RNA polymerase II by the kinase module CAK controls the initiation of transcription. Necessary for the stability of the TFIIH complex and for the presence of normal levels of TFIIH in the cell. . |
Accessions | A0A8I5KQH8 A0A3B3ISL4 ENST00000689809.1 Q6ZYL4 ENST00000607778.2 ENST00000691867.1 ENST00000689383.1 ENST00000648328.1 |